Vivo Capital IX, LLC - May 5, 2022 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role: 10%+ Owner
Signature: /s/ Frank Kung, Managing Member of Vivo Capital IX, LLC
Stock symbol: TARS
Transactions as of: May 5, 2022
Transactions value $: -$65,832
Form type: 4
Date filed: 5/5/2022, 06:55 PM
Previous filing: May 4, 2022
Next filing: Aug 10, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TARS	Common Stock	Sale	-$65.8K	-5.37K	-0.22%	$12.25	2.47M	May 5, 2022	See Footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Vivo Capital IX, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.33, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2	The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.

Content

The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $12.33, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.